Telix share price soars 11% following ‘first commercial quarter’

Rising arrow on a blue graph symbolising a rising share price.Rising arrow on a blue graph symbolising a rising share price.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is pushing higher in trade today.

At the time of writing, the share is trading more than 11% in the green at $6.21 apiece.

Investors are bidding up the Telix share price following the release of its quarterly cash flow statement and activities report for the quarter ended 30 June 2022.

Telix reports 10x revenue increase in Q4

  • Total revenue of $22.5 million from global sales of Illuccix in its first commercial quarter, 10x increase on previous quarter
  • Cash balance of $122 million
  • Cash inflows of $5.4 million, up from around $2 million in the previous quarter
  • $17.4 million invested in R&D, manufacturing and clinical development activities
  • Telix reports it has 5.5 quarters of cash based on net cash used in operations in the June 2022 quarter

What else happened for Telix last quarter?

It was the commercial launch of Illuccix in the US. Telix distributed the product to 140 pharmacies across pharmacy networks in America.

Illuccix (aka TLX591–CDx) is Telix’s prostate imaging product. The company notes that Illuccix commercial sales revenue from the US between 14 April and 30 June 2022 was USD$13.6 million (AUD$19.3 million).

Telix also completed enrolment for its ZIRCON Phase III kidney cancer imaging trial. It now has 300 patients dosed, per the release.

It also signed an in-licence agreement with Lilly to develop the antibody Olaratumab “as a diagnostic and therapeutic radiopharmaceutical agent”.

New Group CFO, Darren Smith, was also appointed into his role, to take effect on 1 August 2022.

Management commentary

Speaking on the results, Telix Managing Director and Group CEO, Dr Christian Behrenbruch said:

The U.S. commercial launch of Illuccix is off to a strong start. This result reflects the efficacy of our differentiated business model in a large and growing market. We’ve delivered doses across the entire country, demonstrating the value of our nationwide pharmacy distribution partnerships and with industryleading on-time delivery.

We are meeting the needs of our customers and patients through reliable service delivery, flexible scheduling and wide accessibility to PSMA-PET imaging. With reimbursement effective 1 July, we expect to see Illuccix revenues grow considerably.

Telix share price snapshot

In the past 12 months, the Telix share price has clipped a 19% gain. A bulk of this was seen in the past month of trade, with shares up 50% in that time.

The post Telix share price soars 11% following ‘first commercial quarter’ appeared first on The Motley Fool Australia.

Should you invest $1,000 in Telix Pharmaceuticals Ltd right now?

Before you consider Telix Pharmaceuticals Ltd, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals Ltd wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

See The 5 Stocks
*Returns as of July 7 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];[property] = defaultValue;

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);

More reading

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s